Looking beyond surveillance, epidemiology, and end results: Patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1529-1535

  Rasco, Drew W ^a   Yan, Jingsheng ^b   Xie, Yang ^b   Dowell, Jonathan E ^a   Gerber, David E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Insurance; Metastatic; Non small cell lung cancer; Practice patterns

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

EID: 77958199124     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e9a00f     Document Type: Article

References (32)

1. Cartei G, Cartei F, Cantone A, et al. Cisplatin-cyclophosphamidemitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 1993;85:794-800. (Pubitemid 23150310)
2. Quoix E, Dietemann A, Charbonneau J, et al. Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV? Results of a randomized study. Bull Cancer 1991;78:341-346.
3. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-836.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
5. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and metaanalysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625.
6. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002;20:1786-1792. (Pubitemid 34273267)
7. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-1246. (Pubitemid 30321574)
8. Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971-4978. (Pubitemid 46638623)
9. Wassenaar TR, Eickhoff JC, Jarzemsky DR, et al. Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancer. J Thorac Oncol 2007;2:722-728.
10. SEER Cancer Statistics Review. National Cancer Institute, 1975-2006. Available at: http://seer.cancer.gov/csr/1975-2006/browse-csr.php. Accessed March 13, 2010.
11. Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010;5:29-33.
12. U.S. Census State and County QuickFacts: Dallas County, TX. Available at: http://quickfacts.census.gov/qfd/states/48/48113.html. Accessed March 13, 2010.
13. Renouf D, Kennecke H, Gill S. Trends in chemotherapy utilization for colorectal cancer. Clin Colorectal Cancer 2008;7:386-389.
14. National Cancer Database Public Benchmark Reports. Available at: http://cromwell.facs.org/BMarks/BMPub/Ver10/bm-reports.cfm. Accessed March 13, 2010.
15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
16. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
17. Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004;22:2587-2593. (Pubitemid 41103745)
18. Pegram M, Forbes J, Pienkowski T, et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer. J Clin Oncol 2007;25: LBA1008.
19. Soto C. TT, Reyes S, Ramirez M, et al. Capecitabine and taxanes in patients with anthracycline-pretreated metastatic breast cancer: sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 2006;24:570.
20. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947. (Pubitemid 30644117)
21. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-147. (Pubitemid 30036347)
22. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342. (Pubitemid 38702844)
23. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26: 2013-2019.
24. Chrischilles EA, Pendergast JF, Kahn KL, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010;28:620-627.
25. Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 2008;9:222-231.
26. Greenberg ER, Chute CG, Stukel T, et al. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med 1988;318:612-617.
27. Yorio JT, Xie Y, Yan J, et al. Lung cancer diagnostic and treatment intervals in the United States: a health care disparity? J Thorac Oncol 2009;4:1322-1330.
28. Bradley CJ, Dahman B, Given CW. Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid. J Clin Oncol 2008;26:5067-5073.
29. Ayanian JZ, Kohler BA, Abe T, et al. The relation between health insurance coverage and clinical outcomes among women with breast cancer. N Engl J Med 1993;329:326-331. (Pubitemid 23210686)
30. Robbins AS, Pavluck AL, Fedewa SA, et al. Insurance status, comorbidity level, and survival among colorectal cancer patients age 18 to 64 years in the National Cancer Data Base from 2003 to 2005. J Clin Oncol 2009;27:3627-3633.
31. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317:771-775. (Pubitemid 28427226)
32. Lang K, Marciniak MD, Faries D, et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009; 63:264-270.